TNF and psoriasis vulgaris: The drug became the first small molecule TNF inhibitor to enter clinical trials with the ongoing recruitment for phase 2 trials in an estimated 240 patients with RA (NCT06073093) and in an estimated 207 patients with plaque psoriasis (NCT06073119).